NeoImmuneTech Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Luke Yun Oh

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	3.7yrs
Durata media del Consiglio di amministrazione	2.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Companies Like NeoImmuneTech (KOSDAQ:950220) Could Be Quite Risky

Aug 13

Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?

Mar 22

AMMINISTRATORE DELEGATO

Luke Yun Oh

less than a year

Mandato

Dr. Luke Yun Suk Oh Ph. D. is President of NeoImmuneTech, Inc. from January 15, 2024 and serves as its Chief Executive Officer since March 29, 2024 and serves as its Chairman since 2024. Dr. Oh is an exper...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Luke Yun Oh	President	less than a year	Nessun dato	Nessun dato
Tae Woo Kim	Chief Financial Officer	no data	Nessun dato	Nessun dato
Goongjin Namgoong	Chief Operating Officer	4.8yrs	Nessun dato	Nessun dato
Byung Lee	Chief Scientific Officer	3.7yrs	Nessun dato	Nessun dato

3.7yrs

Durata media

Gestione esperta: Il team dirigenziale di A950220 è considerato esperto (durata media dell'incarico 3.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Luke Yun Oh	President	less than a year	Nessun dato	Nessun dato
Rafi Ahmed	Member of Scientific Advisory Board	5yrs	Nessun dato	Nessun dato
Soo-Hyoung Kang	Director	no data	Nessun dato	Nessun dato
Jin-Hyoung Kang	Director	3.5yrs	Nessun dato	Nessun dato
Sung-June Hong	Director	less than a year	Nessun dato	Nessun dato
Richard Kim	Member of Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato
Keith Watson	Member of Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato
Hyunseok Kang	Member of Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato
Young Chae	Member of Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato
Benny Chen	Member of Scientific Advisory Board	1.3yrs	Nessun dato	Nessun dato
Su-Hyung Park	Member of Scientific Advisory Board	1.3yrs	Nessun dato	Nessun dato
Choonggoo Kang	Director	less than a year	Nessun dato	Nessun dato

2.3yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di A950220 non è considerato esperto (durata media del mandato 2.3 anni), il che suggerisce un nuovo consiglio.

NeoImmuneTech Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Appoints Luke Oh as President

Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board

No independent directors

NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board

Recent updates

New minor risk - Share price stability

Companies Like NeoImmuneTech (KOSDAQ:950220) Could Be Quite Risky

NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?

New minor risk - Share price stability

NeoImmuneTech, Inc. Appoints Luke Oh as President

Fda Grants Orphan Drug Designation to Neoimmunetech's Nt-I7 for the Treatment of Acute Radiation Syndrome

New minor risk - Share price stability

Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board

No independent directors

New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy in Combination with Pembrolizumab in Relapsed/Refractory (R/R) Gastrointestinal Tumors

NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board

NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

NeoImmuneTech, Inc.'s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors

No independent directors

Neoimmunetech Demonstrates Nt-I7’S Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine At Aacr 2022

NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers

NeoImmuneTech, Inc. Announces the Publication of Preclinical Data Evaluating Lead Asset NT-I7

NeoImmuneTech, Inc. announced that it has received $4.7 million in funding from Hefei SPARK Venture Capital Management Co., Ltd., Kindstar Global (Beijing) Technology, Inc.

NeoImmuneTech, Inc. Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting

Neoimmunetech to Present At Society for Neuro-Oncology

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection

NeoImmuneTech, Inc. Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

NeoImmuneTech, Inc. Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media